journal
https://read.qxmd.com/read/38642927/patient-perspective-and-feasibility-of-home-finger-prick-testing-to-complement-and-facilitate-large-scale-research-in-rheumatology
#1
JOURNAL ARTICLE
Yaëlle R Besten, Laura Boekel, Maurice Steenhuis, Femke Hooijberg, Sadaf Atiqi, Maureen Leeuw, Erik H Vogelzang, Jim Keijser, Sofie Keijzer, Floris C Loeff, Martijn Gerritsen, Sander W Tas, Michael T Nurmohamed, Theo Rispens, Gertjan Wolbink
BACKGROUND: During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect serum samples remotely and increase the overall efficiency of the platform. The aim of the present study was to evaluate the success rate of the finger prick and patients' perspective towards the finger prick. METHODS: Serum samples were collected up to five times during follow-up, either via a venepuncture at the research institute or a finger prick from participants' home...
April 19, 2024: RMD Open
https://read.qxmd.com/read/38642926/classification-of-rheumatoid-arthritis-is-it-time-to-revise-the-criteria
#2
JOURNAL ARTICLE
Guenter Steiner, Patrick Verschueren, Lieve Van Hoovels, Paul Studenic, Xavier Bossuyt
Classification criteria have been developed for rheumatoid arthritis (RA) and other rheumatic diseases in order to gather a homogeneous patient population for clinical studies and facilitate the timely implementation of therapeutic measures. Although classification criteria are not intended to be used for diagnosis, they are frequently used to support the diagnostic process in clinical practice, including clinical decision-making. The 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria for RA are capable of identifying the majority of symptomatic patients with RA already in the earliest stages of the disease who are not yet showing radiographic changes...
April 19, 2024: RMD Open
https://read.qxmd.com/read/38637112/polygenic-risk-score-predicts-earlier-onset-adult-systemic-lupus-erythematosus-and-first-year-renal-diseases-in-a-taiwanese-cohort
#3
JOURNAL ARTICLE
Yen-Ju Chen, Tzu-Hung Hsiao, Ying-Cheng Lin, Wen-Juei Jeng, Chien-Lin Mao, Chia-Yi Wei, Yi-Chung Hsieh, Chih-Jen Huang, Mei-Hung Pan, I-Chieh Chen, Ching-Heng Lin, Yi-Ming Chen, Hwai-I Yang
OBJECTIVES: This study aimed to develop a predictive model using polygenic risk score (PRS) to forecast renal outcomes for adult systemic lupus erythematosus (SLE) in a Taiwanese population. METHODS: Patients with SLE (n=2782) and matched non-SLE controls (n=11 128) were genotyped using Genome-Wide TWB 2.0 single-nucleotide polymorphism (SNP) array. PRS models (C+T, LDpred2, Lassosum, PRSice-2, PRS-continuous shrinkage (CS)) were constructed for predicting SLE susceptibility...
April 18, 2024: RMD Open
https://read.qxmd.com/read/38631846/use-of-risk-chart-algorithms-for-the-identification-of-psoriatic-arthritis-patients-at-high-risk-for-cardiovascular-disease-findings-derived-from-the-project-carma-cohort-after-a-7-5-year-follow-up-period
#4
JOURNAL ARTICLE
Jessica Polo Y La Borda, Santos Castañeda, Elena Heras-Recuero, Fernando Sánchez-Alonso, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, Carolina Pérez-García, Carlos González-Juanatey, Javier Llorca, Miguel Angel Gonzalez-Gay
OBJECTIVE: To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients. METHODS: Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics at tertiary centres for 7.5 years, were retrospectively analysed to test the performance of the Systematic Coronary Risk Assessment (SCORE), the modified version (mSCORE) European Alliance of Rheumatology Associations (EULAR) 2015/2016, the SCORE2 algorithm (the updated and improved version of SCORE) and the QRESEARCH risk estimator version 3 (QRISK3)...
April 17, 2024: RMD Open
https://read.qxmd.com/read/38626930/application-of-the-2023-acr-eular-classification-criteria-for-calcium-pyrophosphate-deposition-disease-in-a-seronegative-rheumatoid-arthritis-cohort
#5
LETTER
Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torne
No abstract text is available yet for this article.
April 15, 2024: RMD Open
https://read.qxmd.com/read/38609322/risk-of-extended-major-adverse-cardiovascular-event-endpoints-with-tofacitinib-versus-tnf-inhibitors-in-patients-with-rheumatoid-arthritis-a-post-hoc-analysis-of-a-phase-3b-4-randomised-safety-study
#6
RANDOMIZED CONTROLLED TRIAL
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
OBJECTIVES: Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance. METHODS: Patients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi...
April 12, 2024: RMD Open
https://read.qxmd.com/read/38609321/understanding-the-psychosocial-determinants-of-effective-disease-management-in-rheumatoid-arthritis-to-prevent-persistently-active-disease-a-qualitative-study
#7
JOURNAL ARTICLE
Nkasi Stoll, Mrinalini Dey, Sam Norton, Maryam Adas, Ailsa Bosworth, Maya H Buch, Andrew Cope, Heidi Lempp, James Galloway, Elena Nikiphorou
BACKGROUND: According to epidemiological studies, psychosocial factors are known to be associated with disease activity, physical activity, pain, functioning, treatment help-seeking, treatment waiting times and mortality in people with rheumatoid arthritis (RA). Limited qualitative inquiry into the psychosocial factors that add to RA disease burden and potential synergistic interactions with biological parameters makes it difficult to understand patients' perspectives from the existing literature...
April 12, 2024: RMD Open
https://read.qxmd.com/read/38609320/analysis-of-belimumab-prescription-and-outcomes-in-a-10-year-monocentric-cohort-is-there-an-advantage-with-early-use
#8
JOURNAL ARTICLE
Chiara Tani, Dina Zucchi, Chiara Cardelli, Elena Elefante, Viola Signorini, Davide Schilirò, Giancarlo Cascarano, Luca Gualtieri, Anastasiya Valevich, Giulia Puccetti, Linda Carli, Chiara Stagnaro, Marta Mosca
OBJECTIVE: The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE). METHODS: This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit...
April 12, 2024: RMD Open
https://read.qxmd.com/read/38609319/comparison-of-active-tuberculosis-occurrence-associated-with-janus-kinase-inhibitors-and-biological-dmards-in-rheumatoid-arthritis
#9
JOURNAL ARTICLE
Yun-Kyoung Song, Jaehee Lee, Junwoo Jo, Jin-Won Kwon
OBJECTIVES: This study aimed to evaluate the risk of tuberculosis associated with the use of Janus kinase (JAK) inhibitors or biological disease-modifying antirheumatic drugs (bDMARDs) in patients diagnosed with rheumatoid arthritis (RA) in South Korea. METHODS: In this nationwide matched-cohort study, we retrospectively identified adult patients with new-onset RA from the National Health Insurance Service database who were prescribed bDMARDs or JAK inhibitors and recently underwent latent tuberculosis infection (LTBI) screening during 2012‒2021, and followed them up until the end of 2022 for the development of active tuberculosis...
April 12, 2024: RMD Open
https://read.qxmd.com/read/38599656/associations-between-life-course-longitudinal-growth-and-hip-shapes-at-ages-60-64-years-evidence-from-the-mrc-national-survey-of-health-and-development
#10
JOURNAL ARTICLE
Katherine Ann Staines, Fiona R Saunders, Alex Ireland, Richard M Aspden, Jennifer S Gregory, Rebecca J Hardy, Rachel Cooper
OBJECTIVE: We sought to examine associations between height gain across childhood and adolescence with hip shape in individuals aged 60-64 years from the Medical Research Council National Survey of Health and Development, a nationally representative British birth cohort. METHODS: Height was measured at ages 2, 4, 6, 7, 11 and 15 years, and self-reported at age 20 years. 10 modes of variation in hip shape (HM1-10), described by statistical shape models, were previously ascertained from DXA images taken at ages 60-64 years...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599655/utility-of-testing-for-third-generation-anticyclic-citrullinated-peptide-anti-ccp3-antibodies-in-individuals-who-present-with-new-musculoskeletal-symptoms-but-have-a-negative-second-generation-anticyclic-citrullinated-peptide-anti-ccp2-antibody-test
#11
JOURNAL ARTICLE
Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
OBJECTIVES: To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2-). METHODS: 469 anti-CCP2- individuals underwent baseline anti-CCP3 testing (QUANTA Lite CCP3; Inova Diagnostics) and received a post enrolment 12-month questionnaire. A rheumatologist confirmed or excluded diagnosis of IA...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599652/myocardial-infarction-in-a-population-based-cohort-of-patients-with-biopsy-confirmed-giant-cell-arteritis-in-southern-sweden
#12
JOURNAL ARTICLE
Pavlos Stamatis, Moman Aladdin Mohammad, Karl Gisslander, Peter A Merkel, Martin Englund, Carl Turesson, David Erlinge, Aladdin J Mohammad
OBJECTIVES: To determine the incidence rate (IR) of myocardial infarction (MI), relative risk of MI, and impact of incident MI on mortality in individuals with biopsy-confirmed giant cell arteritis (GCA). METHODS: MIs in individuals diagnosed with GCA 1998-2016 in Skåne, Sweden were identified by searching the SWEDEHEART register, a record of all patients receiving care for MI in a coronary care unit (CCU). The regional diagnosis database, with subsequent case review, identified GCA patients receiving care for MI outside of a CCU...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599651/distinctive-profile-of-monomeric-and-polymeric-anti-ssa-ro52-immunoglobulin-a1-isoforms-in-saliva-of-patients-with-primary-sj%C3%A3-gren-s-syndrome-and-sicca
#13
JOURNAL ARTICLE
Samantha Chiang, Tristan Grogan, Sarah Kamounah, Fang Wei, Nabihah Tayob, Ju Yeon Kim, Jin Kyun Park, David Akin, David A Elashoff, Anne Marie Lynge Pedersen, Yeong Wook Song, David T W Wong, David Chia
OBJECTIVE: Primary Sjögren's syndrome (pSS) is the second most common chronic autoimmune connective tissue disease. Autoantibodies, immunoglobulin (IgG) anti-SSA/Ro, in serum is a key diagnostic feature of pSS. Since pSS is a disease of the salivary gland, we investigated anti-SSA/Ro52 in saliva. METHODS: Using a novel electrochemical detection platform, Electric Field-Induced Release and Measurement, we measured IgG/M/A, IgG, IgA, IgA isotypes (IgA1 and IgA2) and IgA1 subclasses (polymeric and monomeric IgA1) to anti-SSA/Ro52 in saliva supernatant of 34 pSS, 35 dry eyes and dry mouth (patients with Sicca) and 41 health controls...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599650/association-of-clinical-response-criteria-and-disease-activity-levels-with-axial-spondyloarthritis-core-domains-results-from-two-phase-3-randomised-studies-be-mobile-1-and-2
#14
JOURNAL ARTICLE
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, Philip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
OBJECTIVE: To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). METHODS: Patients in BE MOBILE 1 and 2 achieving different levels of response or disease activity (Assessment of SpondyloArthritis International Society (ASAS) and Ankylosing Spondylitis Disease Activity Score (ASDAS) response criteria, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50)) at week 52 were pooled, regardless of treatment arm...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599649/risk-of-developing-psoriatic-arthritis-in-psoriasis-cohorts-with-arthralgia-exploring-the-subclinical-psoriatic-arthritis-stage
#15
JOURNAL ARTICLE
Alen Zabotti, Filippo Fagni, Laure Gossec, Ivan Giovannini, Michael Sticherling, Annarita Tullio, Xenofon Baraliakos, Gabriele De Marco, Salvatore De Vita, Enzo Errichetti, Luca Quartuccio, Ettore Silvagni, Josef S Smolen, Ilaria Tinazzi, Abdulla Watad, Georg Schett, Dennis G McGonagle, David Simon
OBJECTIVE: Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis. METHODS: Patients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts...
April 10, 2024: RMD Open
https://read.qxmd.com/read/38599657/correction-significance-of-structural-changes-in-the-axial-skeleton-in-patients-with-axial-spondyloarthritis-how-important-are-lesions-in-the-sacroiliac-joint
#16
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2024: RMD Open
https://read.qxmd.com/read/38599654/long-term-clinical-and-radiological-effectiveness-and-safety-of-ultralow-doses-of-rituximab-in-rheumatoid-arthritis-observational-extension-of-the-redo-trial
#17
JOURNAL ARTICLE
Nathan den Broeder, Lise Verhoef, Yaël A de Man, Marc R Kok, Rogier Thurlings, Wilfred van der Weele, Bart Jf van den Bemt, Frank Hj van den Hoogen, Aatke van der Maas, Alfons A den Broeder
BACKGROUND: The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per 6 months) compared with standard low-dose rituximab (RTX, 1000 mg per 6 months). We performed an observational extension study of the REDO trial to assess long-term effectiveness. METHODS: Patients from the REDO trial were followed from start of the trial to censoring in April 2021...
April 9, 2024: RMD Open
https://read.qxmd.com/read/38599653/incidence-and-outcome-of-covid-19-following-vaccine-and-hybrid-immunity-in-patients-on-immunosuppressive-therapy-identification-of-protective-post-immunisation-anti-rbd-antibody-levels-in-a-prospective-cohort-study
#18
JOURNAL ARTICLE
Hilde S Ørbo, Kristin H Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne T Tveter, Ingrid E Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella A Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
OBJECTIVES: To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive medication. METHODS: IMIDs on immunosuppressives and healthy controls (HC) receiving SARS-CoV-2 vaccines were included in this prospective observational study...
April 9, 2024: RMD Open
https://read.qxmd.com/read/38599648/work-related-physical-strain-and-development-of-joint-inflammation-in-the-trajectory-of-emerging-inflammatory-and-rheumatoid-arthritis-a-prospective-cohort-study
#19
JOURNAL ARTICLE
Bastiaan T van Dijk, Anna M P Boeren, Sarah J H Khidir, Nikolet K den Hollander, Annette H M van der Helm-van Mil
OBJECTIVES: Rheumatoid arthritis (RA) mainly affects small joints. Despite the mechanical function of joints, the role of mechanical stress in the development of arthritis is insufficiently understood. We hypothesised that mechanical stress/physical strain is a risk factor for joint inflammation in RA. Therefore, we studied work-related physical strain in subjects with clinically suspected arthralgia (CSA) as a risk factor for the presence of imaging-detected subclinical joint inflammation and the development of clinical arthritis/RA...
April 9, 2024: RMD Open
https://read.qxmd.com/read/38580353/correction-validation-of-sparcc-mri-retic-e-tools-for-increasing-scoring-proficiency-of-mri-sacroiliac-joint-lesions-in-axial-spondyloarthritis
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 5, 2024: RMD Open
journal
journal
52478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.